SCHLAP1 and prostate cancer: Apart from Gleason score, the increased expression of SChLAP1 was validated as a significantly prognostic biomarker for metastatic prostate cancer increased with prostate cancer progression and predicted the poor clinical outcome in patients with localized prostate cancer following radical prostatectomy and patients with lethal prostate cancer [27, 31, 47] .